Russell Investments Group Ltd. Boosts Stock Position in Alphatec Holdings, Inc. $ATEC

Key Points

• Russell Investments Group Ltd. increased its stake in Alphatec Holdings, Inc. by 68.3% during the 1st quarter, holding approximately 336,463 shares valued at $3.41 million.
• Several institutional investors, including Comerica Bank and Quarry LP, also boosted their stakes in Alphatec, indicating strong interest in the company's stock.
• Alphatec reported earnings of $0.02 per share for the last quarter, exceeding analysts' expectations, with revenues up 27.5% year-over-year, totaling $185.54 million.

Russell Investments Group Ltd. grew its holdings in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 68.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 336,463 shares of the medical technology company's stock after acquiring an additional 136,577 shares during the quarter. Russell Investments Group Ltd. owned 0.23% of Alphatec worth $3,412,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of ATEC. Nuveen LLC acquired a new position in shares of Alphatec in the first quarter valued at approximately $135,874,000. Vanguard Group Inc. boosted its holdings in shares of Alphatec by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company's stock worth $60,990,000 after buying an additional 45,792 shares in the last quarter. Royal Bank of Canada boosted its holdings in shares of Alphatec by 171.2% during the 4th quarter. Royal Bank of Canada now owns 3,185,283 shares of the medical technology company's stock worth $29,240,000 after buying an additional 2,010,806 shares in the last quarter. Nuveen Asset Management LLC boosted its holdings in shares of Alphatec by 78.4% during the 4th quarter. Nuveen Asset Management LLC now owns 2,584,996 shares of the medical technology company's stock worth $23,730,000 after buying an additional 1,136,330 shares in the last quarter. Finally, Cerity Partners LLC lifted its holdings in shares of Alphatec by 1.6% in the 1st quarter. Cerity Partners LLC now owns 1,859,137 shares of the medical technology company's stock worth $18,852,000 after purchasing an additional 30,072 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company's stock.

Alphatec Trading Down 0.8%

Shares of Alphatec stock traded down $0.13 during midday trading on Friday, reaching $15.90. 1,651,222 shares of the company's stock traded hands, compared to its average volume of 3,265,962. The company has a market cap of $2.35 billion, a PE ratio of -14.07 and a beta of 1.05. The stock has a 50 day moving average of $12.88 and a 200-day moving average of $11.73. Alphatec Holdings, Inc. has a 12 month low of $4.88 and a 12 month high of $16.47. The company has a debt-to-equity ratio of 23.22, a quick ratio of 1.77 and a current ratio of 2.88.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings results on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.08. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%.The company had revenue of $185.54 million for the quarter, compared to analysts' expectations of $178.85 million. During the same period in the prior year, the firm earned ($0.29) earnings per share. The firm's revenue for the quarter was up 27.5% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on ATEC shares. Piper Sandler reissued an "overweight" rating and issued a $15.00 price target (up from $13.00) on shares of Alphatec in a research report on Friday, May 2nd. Wall Street Zen upgraded Alphatec from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Barclays reiterated an "overweight" rating and set a $22.00 price target (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Needham & Company LLC reiterated a "buy" rating and set a $16.00 price target on shares of Alphatec in a research note on Friday, May 2nd. Finally, Lake Street Capital upgraded Alphatec to a "buy" rating and set a $18.00 price target for the company in a research note on Monday, June 16th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $18.50.

Insider Buying and Selling at Alphatec

In related news, General Counsel Tyson Eliot Marshall sold 18,092 shares of Alphatec stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $14.91, for a total transaction of $269,751.72. Following the sale, the general counsel owned 438,331 shares of the company's stock, valued at approximately $6,535,515.21. This trade represents a 3.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Craig E. Hunsaker sold 186,122 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The shares were sold at an average price of $12.34, for a total value of $2,296,745.48. Following the transaction, the executive vice president owned 1,463,896 shares of the company's stock, valued at $18,064,476.64. This represents a 11.28% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 410,247 shares of company stock valued at $5,376,804. 20.90% of the stock is owned by company insiders.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.